IP Library Granted Patent US 10,258,677
Granted Patent B2
US 10,258,677 · App. 15/135,255 · Granted Apr 16, 2019

Continuous cell programming devices

Inventors: David J. Mooney (Sudbury, MA); Omar Abdel-Rahman Ali (Cambridge, MA); Glenn Dranoff (Sudbury, MA)
Assignees: President and Fellows of Harvard College; Dana-Farber Cancer Institute, Inc.
A61K39/0011A61K31/4745A61K31/708A61K31/7088A61K38/193A61K39/39A61K45/06A61K2039/54A61K2039/55516A61K2039/55522A61K2039/55561A61K2039/55588A61K2039/6093
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,258,677
App. No.
15/135,255
Granted
Apr 16, 2019
Kind
B2
Abstract

The present invention comprises compositions, methods, and devices for creating an infection-mimicking environment within a polymer scaffold to stimulate antigen-specific dendritic cell activation. Devices of the present invention are used to provide protective immunity to subjects against infection and cancer.

Claims (13)

1. A device comprising

a scaffold polymer selected from the group consisting of poly-lactide-co-glycolide (PLG), alginate, xanthan gum, gellan, or emulsan;

a tumor antigen;

a recruitment composition comprising a cytokine, which comprises a granulocyte macrophage colony stimulating factor (GM-CSF), that recruits one or more dendritic cells to temporarily reside within said device; and

a positively charged polyethylenimine (PEI)-condensed toll-like receptor-9 (TLR-9)-activating CpG-ODN (PEI-CpG-ODN) which is retained in or on said scaffold polymer,

wherein said PEI-CpG-ODN is present in an amount effective to overcome the trapping effect of the cytokine on said dendritic cells.

2. The device of claim 1 , wherein the recruitment composition is encapsulated.

3. The device of claim 1 , wherein said tumor antigen comprises a biopsy tumor cell lysate.

4. The device of claim 1 , wherein the scaffold polymer is alginate.

5. The device of claim 1 , wherein the scaffold polymer is PLG.

6. The device of claim 1 , wherein the CpG-ODN is CpG-ODN 1826.

7. The device of claim 1 , wherein said PEI-CpG-ODN comprises nanoparticles.

8. The device of claim 1 , wherein said PEI-CpG-ODN is retained in said scaffold polymer.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2016
From: MOONEY, DAVID J.; ALI, OMAR ABDEL-RAHMAN
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 039688/0963 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2016
From: DRANOFF, GLENN
To: DANA-FARBER CANCER, INSTITUTE, INC.
Reel/Frame 039689/0004 →
Continuity (4)
Division 12867426
Provisional Application 61143630 · Jan 9, 2009
Provisional Application 61065672 · Feb 13, 2008
Related Publication 20160220667A1 · Aug 4, 2016
Cited By (5)
US 12,258,430 US 12,274,744 US 12,427,118 US 12,514,865 US 12,661,433